Activist investor Starboard Value has amassed a stake in chip maker Qorvo that’s worth half a billion dollars, according to a ...

There has been a shakeup in markets since Donald Trump’s election, and investors have been positioning their portfolios to ...

This health news update covers Bayer's $100 million payout over PCBs, Biogen's future strategy, Pfizer's appeal in an SEC ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Wedmont Private Capital lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 17.7% in the fourth ...

Brookstone Capital Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.9% in the fourth ...

A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pfizer expects the acquisition of Seagen to contribute more than $10 billion in 2030 risk-adjusted revenues with potential significant growth beyond 2030.